Shares of NantKwest, Inc. (NASDAQ:NK) have earned an average rating of “Hold” from the six ratings firms that are covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and two have given a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $5.13.

NK has been the subject of a number of recent research reports. Zacks Investment Research raised NantKwest from a “hold” rating to a “buy” rating and set a $5.75 price target for the company in a report on Wednesday, October 11th. Citigroup set a $3.00 target price on NantKwest and gave the stock a “sell” rating in a report on Monday, August 14th. Finally, BidaskClub downgraded NantKwest from a “hold” rating to a “sell” rating in a report on Tuesday, August 8th.

Shares of NantKwest (NASDAQ:NK) opened at $4.83 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.47 and a quick ratio of 5.47. NantKwest has a 12 month low of $2.71 and a 12 month high of $8.45.

In other news, Director Steve Gorlin sold 39,604 shares of NantKwest stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $5.93, for a total transaction of $234,851.72. Following the transaction, the director now directly owns 246,280 shares in the company, valued at approximately $1,460,440.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 70.19% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of NK. JPMorgan Chase & Co. boosted its position in shares of NantKwest by 155.8% in the third quarter. JPMorgan Chase & Co. now owns 25,579 shares of the biotechnology company’s stock worth $140,000 after buying an additional 71,444 shares during the period. SG Americas Securities LLC boosted its position in shares of NantKwest by 254.3% in the third quarter. SG Americas Securities LLC now owns 49,356 shares of the biotechnology company’s stock worth $270,000 after buying an additional 35,424 shares during the period. Russell Investments Group Ltd. acquired a new stake in shares of NantKwest in the third quarter worth $139,000. California State Teachers Retirement System boosted its position in NantKwest by 58.1% during the second quarter. California State Teachers Retirement System now owns 54,154 shares of the biotechnology company’s stock valued at $411,000 after purchasing an additional 19,900 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in NantKwest by 1,110.9% during the second quarter. The Manufacturers Life Insurance Company now owns 27,572 shares of the biotechnology company’s stock valued at $210,000 after purchasing an additional 25,295 shares during the last quarter. Institutional investors and hedge funds own 19.14% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “NantKwest, Inc. (NK) Given Consensus Recommendation of “Hold” by Analysts” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/11/30/nantkwest-inc-nk-given-consensus-recommendation-of-hold-by-analysts.html.

About NantKwest

Receive News & Ratings for NantKwest Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest Inc. and related companies with MarketBeat.com's FREE daily email newsletter.